Related Experiment Video
Updated: May 5, 2026
11:06
Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells
Published on: February 24, 2014
13.0K
Genetic polymorphisms and platinum-induced hematological toxicity: a systematic review
Yi Zheng1, Mimi Tang2, Zheng Deng3,4
1Hunan Provincial Maternal and Child Health Care Hospital, Changsha, China.
Frontiers in Pharmacology
|September 5, 2024
Summary
This review identifies genetic biomarkers for platinum-induced hematological toxicity, highlighting promising variants like GSTP1 rs1695 and ERCC1 rs11615. Further validation is needed due to inconsistent results and methodological limitations.
Area of Science:
- Pharmacogenomics
- Oncology
- Clinical Genetics
Background:
- Platinum-based chemotherapy causes severe hematological toxicity, impacting treatment adherence.
- Genetic variations may influence this toxicity, but existing research is controversial and lacks comprehensive review.
- Identifying reliable genetic biomarkers is crucial for personalized cancer treatment.
Purpose of the Study:
- To systematically review and identify genetic biomarkers associated with platinum-induced hematological toxicity in cancer patients.
- To provide an overview of current evidence and highlight potential genetic markers for further investigation.
Main Methods:
- Systematic literature search of PubMed, Embase, and Web of Science databases up to January 28, 2022.
- Inclusion of studies evaluating genetic variants and platinum-related hematological toxicity with defined endpoints and scoring systems.
- Quality assessment using the STREGA checklist and narrative synthesis of results.
Main Results:
- 83 studies analyzed, examining over 682 single-nucleotide polymorphisms (SNPs) across 110 genes.
- Inconsistent findings and methodological issues (small sample size, diverse endpoints) were noted.
- 11 SNPs in 10 genes showed consistent results across multiple populations, with GSTP1 rs1695, ERCC1 rs11615, ERCC1 rs3212986, and XRCC1 rs25487 being most promising.
Conclusions:
- Several genetic variations show potential as biomarkers for platinum-induced hematological toxicity.
- Methodological limitations necessitate validation in larger, well-designed studies.
- Future research should focus on robust methodologies for definitive biomarker identification.
More Related Videos
Related Concept Videos
01:27Principles of Pharmacogenetics: Types of Genetic Variants
143
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
143
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
160
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
160
01:27Pharmacogenetics of Drug Metabolism: Overview
195
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
195
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
100
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
100
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84
01:16Drug toxicity: Idiosyncratic Reactions
232
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
232